Joaquina Baranda is an Oncology physician affiliated with The University of Kansas Cancer Center. OpenAlex indexes 173 publications with 3,958 citations (h-index 27); ClinicalTrials.gov lists 4 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
2650 Shawnee Mission Pkwy
Westwood, KS 662052003
Telephone
913-588-1227Provider last certified this registry record 23 Aug 2023.
Clinical trials
- A Window of Opportunity Trial of Intratumoral Injection of Copaxone® in Patients With Percutaneously Accessible Tumors
Sponsor: University of Kansas Medical Center
- A Pilot Trial of Atorvastatin in Tumor Protein 53 (p53) -Mutant and p53 Wild-Type Malignancies
Sponsor: Joaquina Baranda
- A Trial of Irinotecan and BKM120 in Previously Treated Advanced Colorectal Cancer
Sponsor: University of Kansas Medical Center
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
2 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Merck Sharp & Dohme LLCProgram year20231 payment
- Genentech, Inc.Program year20221 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
NIH funding
2 NIH research awards on record, funded 2019–2026 per NIH RePORTER. The latest:
- Increasing Access and Participation to Early Phase Clinical Trials
University of Kansas Medical Center
FY2026$159,574R50CA290098 - Increasing Access and Participation to Early Phase Clinical Trials
University of Kansas Medical Center
FY2025$159,574R50CA290098 - Increasing Access and Participation to Early Phase Clinical Trials to the Underrepresented Populations
University of Kansas Medical Center
FY2024$159,574R50CA290098
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Enfortumab vedotin (EV) in triple-negative breast cancer (TNBC) and HR+/HER2- breast cancer (BC) cohorts of EV-202.
Journal of Clinical Oncology
2024 - Equitable Access to Clinical Trials: How Do We Achieve It?
American Society of Clinical Oncology Educational Book
2023
Similar KOLs
Other experts from the same institution or the same specialty.
Weijing Sun, MD
The University of Kansas Cancer Center
Andrea Jewell, MD
The University of Kansas Cancer Center
Marc Hoffmann, MD
The University of Kansas Cancer Center
Haitham Abdelhakim, MBCHB
The University of Kansas Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”